This page is updated frequently with new Peritoneal-related patent applications.
|| List of recent Peritoneal-related patents
|Universal portable machine for online hemodiafiltration using regenerated dialysate|
Manifolds suitable for use in hemodialysis, hemofiltration, hemodiafiltration, and peritoneal dialysis are provided. One or more of the manifolds can include a manifold body and an external tube.
Fresenius Medical Care Holdings, Inc.
|Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy|
The present invention provides methods for treatment or prophylaxis of viruses, particularly influenza virus, by administration of agents, particularly neutralizing antibodies or active fragments thereof, directly to the respiratory tract, including by intranasal or inhalation administration. The invention provides compositions suitable for intranasal or inhalation treatment and administration.
|Site 2 insulin analogues|
An insulin analogue contains one or more modifications at a distinct protein surface comprising one or more of the residues at position b13, b17, a12, a13, and/or a17. Formulations of the above analogues at successive strengths u-100 to u-1000 in soluble solutions a at least ph value in the range 6.8-8.0 either in the presence of zinc ions at a molar ratio of 2.2-10 zinc ions per six insulin analogue monomers or in the presence of fewer than 1 zinc ions per six insulin analogue monomers.
Case Western Reserve University
|Medical treatment system and methods using a plurality of fluid lines|
A medical treatment system, such as peritoneal dialysis system, may include control and other features to enhance patient comfort and ease of use. For example, a peritoneal dialysis system may include a control system that can adjust the volume of fluid infused into the peritoneal cavity to prevent the intraperitoneal fluid volume from exceeding a pre-determined amount.
Deka Products Limited Partnership
|Ultraviolet disinfection unit|
An ultraviolet (uv) disinfection unit for disinfecting catheter line connections is provided. The unit can be used to disinfect solution set and transfer set catheters used for peritoneal dialysis.
|Ventriculoperitoneal shunt with pressure responsive element|
A ventriculoperitoneal shunt includes a proximal catheter, a distal catheter, a shunt valve operably coupling the proximal catheter to the distal catheter, and a contrast container containing contrast material configured to change acoustic impedance proportionally to a change in pressure applied to the contrast container.. .
The Johns Hopkins University
|Use of the pat nonapeptide in the treatment and prevention of neurodegenerative diseases|
A pat nonapeptide of formula eaksqggsd can be used to treat or prevent neurodegenerative diseases such as alzheimer's disease, parkinson's disease, huntington's disease and amyotrophic lateral sclerosis. Pharmaceutical compositions containing the pat nonapeptide can be formulated for administration by parenteral route, including the subcutaneous, intraperitoneal, intravenous or intranasal routes..
|Drain and fill logic for automated peritoneal dialysis|
A system for performing a peritoneal dialysis therapy includes at least one dialysis fluid pump, and a control unit operable with the at least one dialysis fluid pump to perform a plurality of peritoneal dialysis cycles, the cycles including a fill phase, a dwell phase and a drain phase. The control unit configured to (i) store a previously entered continuous cycling peritoneal dialysis (“ccpd”) therapy having a total prescribed fresh dialysate fill volume delivered over n cycles, the cycles performed over a total therapy duration, and (ii) automatically convert the ccpd therapy into a tidal peritoneal dialysis therapy having n+1 cycles, less a number of cycles already completed during the ccpd therapy, using the total prescribed fresh dialysis fill volume, and maintaining the total therapy duration..
Baxter Healthcare S.a.
|Intradialytic administration of sodium thiosulfate|
The invention provides a source of sodium thiosulfate via the dialysate used to cleanse the bool of toxic and metabolic waste in the patients undergoing hemodialysis, peritoneal dialysis, or gastro-intestinal dialysis for treatment of end-stage or near end-stage chronic renal disease. In the method of the invention, dialysis solution components contain therapeutic amounts of sodium thiosulfate, which when fully reconstituted for use as a single solution, deliver 20-130 mg/dl of dialysate..
A rotatable door latch for a door hingedly attached the housing of a device, which in some embodiments may be a medical device for handling fluids, such as a peritoneal dialysis cycler with pump cassette. In an embodiment, the door is configured to close over an installed cassette against a front panel of the housing, the door latch configured to capture the head of a post mounted to the housing.
Deka Products Limited Partnership
Cancer vaccines and vaccination methods
Compositions of multipeptide vaccines comprising at least seven tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from at least seven tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating gynecological and peritoneal cancers using such vaccines..
Immunocellular Therapeutics, Ltd
Isoxazole compound for the treatment of cancer
The use of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide or a tautomer thereof or a pharmaceutically acceptable salt or a hydrate or a solvate for the treatment of cancer of the bladder, the colon, the liver, the lung, the breast, the vagina, the ovaries, the pancreas, the kidney, the stomach, the gastrointestinal tract, the prostate, the head and neck, the peritoneal cavity, the thyroid, the bone, the brain, the central nervous system and/or the blood and/or for the treatment of myelodysplastic syndrome, systemic mastocytosis, von hippel-lindau syndrome, multicentric castleman disease and/or psioriasis.. .
Method for preparing a medical solution for the manufacture of a medicament for peritoneal dialysis
Method for preparing a medical solution, comprising the steps of a) providing a solution comprising one or more acetylated or deacetylated amino sugar/sugars in at least one compartment of a container at a ph from 2.5 to 5.0, and b) terminal sterilisation of said at least one compartment and the contents therein, is disclosed, as well as a solution used for preparing the medical solution, a container containing said solution, and use of said solution for the manufacture of a medicament for peritoneal dialysis.. .
Fresenius Medical Care Deutschland Gmbh
Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types
The present invention discloses and claims methods and compositions for the treatment of platinum and/or taxane cancer treating agent-resistant/-refractory sub-populations and/or the mucinous adenocarcinoma sub-type of ovarian cancer subjects with the silicon-containing highly lipophilic camptothecin derivative (hlcd), karenitecin (also known as bnp1350; cositecan; 7-[(2′-trimethylsilyl)ethyl]-20(s) camptothecin). The administration of karenitecin by intravenous (i.v.) and/or oral methodologies are also disclosed and claimed.
Bionumerik Pharmaceuticals, Inc.
Method for identifying a bacterial infection
Method for identifying a bacterial infection the present application concerns a method for identifying the nature of a bacterial infection from a peritoneal sample, in particular, whether it is a gram-negative or gram-positive infection, based upon the determination of one or more cellular and/or humoral markers in a sample.. .
University College Cardiff Consultants Limited
Targeted polymeric inflammation-resolving nanoparticles
Sub-100 micron multimodal nanoparticles have four main components: 1) a target element (peptides, lipids, antibodies, small molecules, etc.) that can selectively bind to cells, tissues, or organs of the body; 2) a diagnostic agent such as a fluorophore or nmr contrast agent that allows visualization of nanoparticles at the site of delivery and/or a therapeutic or prophylactic agent; 3) an outside “stealth” layer that allows the particles to evade recognition by immune system components and increase particle circulation half-life; and 4) a biodegradable polymeric material, forming an inner core which can carry therapeutics and release the payloads at a sustained rate after systemic, intraperitoneal, or mucosal administration. These particles possess excellent stability, high loading efficiency, multiple agent encapsulation, targeting and imaging.
The Trustees Of Columbia University
Method and spinal cooling
A method for exchanging heat with a patient's spinal column incident to spinal surgery or to relieve a patient for a hypoxia condition of the spine. A closed loop heat exchange catheter is percutaneously advanced into the retroperitoneal space of the patient or into the vasculature, and then heat exchange fluid is circulated through the catheter to cool the spinal column..
Zoll Circulation, Inc.
Peritoneal dialysis system and method
A peritoneal dialysis machine that includes a base, a boiling vessel, a condenser, a fluid storage vessel, a sterilizing uv lamp, a fluid mixer, a dialysate cassette, a boiling vessel demineralizing system, and an optional fluid storage vessel rinsing system. The peritoneal dialysis machine automatically generates a predetermined volume of distilled water each day.
System for producing tissue-engineered material
A system for producing a tissue-engineered material includes a hollow member and a mechanical stimulating unit. The hollow member is adapted to be implanted in a peritoneal cavity, and is to be positioned in the peritoneal cavity in a manner that a part of the hollow member contacts an inner wall surface of the peritoneal cavity for enabling formation of a biological tissue that encapsulates the hollow member.
National Cheng Kung University
Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors
This invention relates to novel compounds which are inhibitors of the rearranged during transfection (ret) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to ret dysfunction or where modulation of ret activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (ibs) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, von hippel-lindau syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased ret kinase activity.. .
Glaxosmithkline Intellectual Property Development Limited
Dialysis implant and methods of use
A device and methods for treating renal failure are disclosed. One embodiment of the device is an implantable peritoneal dialysis device.
Sequana Medical Ag
Methods for reducing fibrosis induced by peritoneal dialysis
The disclosure relates to a method of preventing, inhibiting, or reducing fibrosis, the incidence of fibrosis or the progression of fibrosis associated with peritoneal dialysis, during or after peritoneal is administered. More specifically, the methods relates to using intraperitoneal administration of activated protein c (apc) possessing cytoprotective or anti-inflammatory activity, to reduce the incidence or progression of fibrosis associated with peritoneal dialysis.
Saint Louis University
Axially split foam peritoneal dialysis catheter design with functional coatings
The present disclosure provides a dialysis device for peritoneal dialysis. The device comprises a proximal tubular portion comprising a plurality of proximal lumens and a distal tubular portion comprising a plurality of independent tubes.
Cook Medical Technologies Llc
Transfer catheter for ultraviolet disinfection
Disclosed herein are devices and methods related to uv disinfection of a transfer catheter during peritoneal dialysis. The transfer catheter comprises a first and second end, the second end comprising a transfer valve.
A medical device, preferably for peritoneal dialysis, is described which comprises a film tube.. .
Auto-graft bio-synthetic mesh for ventral and parastomal hernia repair and attachment as well as a suture clip
An auto-graft bio-synthetic mesh and a method of application for wound closure is described. The mesh is utilized for wound closure wherein an abdominal incision is effected through the peritoneum and the rectus abdominal sheath of the rectus muscle such as when repairing ventral or paracoslostomy hernias.
Antimicrobial housing and cover for a medical device
A method for immobilizing dyes and antimicrobial agents on a polymeric cover or housing for a medical device is disclosed and described. The surface may be that of a catheter, a connector, a drug vial spike, a bag spike, a prosthetic device, an endoscope, a surface of an infusion pump, a key pad, a touch screen or a handle.
Baxter Healthcare S.a.
Pharmaceutical composition containing conventional liposomes and prolonged-circulation liposomes for the treatment of visceral leishmaniasis
The present invention relates to a pharmaceutical composition for treating visceral leishmaniasis, characterized in that it comprises the association of conventional liposomes and prolonged-circulation liposomes with a leishmanicidal-drug delivery system. Said composition may be used in the preparation of a medicinal product for treating leishmaniasis and may be administered intramuscularly, subcutaneously, intraperitoneally or intravenously.
FundaÇao De Amparo A Pesquisa Do Estado De Minas Gerais- Fapemig
Method of adsorption of ions from a dialysis fluid
A method of adsorption of potassium ions from a peritoneal dialysis fluid, which has been removed from the peritoneal cavity of a patient performing peritoneal dialysis for subsequent recirculation and introduction into the peritoneal cavity of the patient. The peritoneal dialysis fluid is passed through a potassium adsorbent, such as a zeolite, which has been pre-equilibrated with an equilibration fluid comprising na+, ca2+, mg2+, cl−, lactate, in substantially the same concentration as in the peritoneal dialysis fluid and which equilibration fluid lacks k+.
Laparoscopic tool with obturator
A laparoscopic device with obturator. The device facilitates extraction of specimens from a female subject's abdominal cavity through the subject's vagina by also facilitating the suturing of a mesh to the anterior and posterior walls of the subject's vagina.
Tissue debris and blood collection device and methods of use thereof
Protective barrier for laparoscopy is provided and comprises bag with closed bottom, wall(s), and open end. Bag may comprise drawstring and/or optional flexible stay(s), in internal channel around periphery of open end of bag.
Laparoscopic Innovations Llc
A medical device tunneling system, and a method of using the same, to subcutaneously route trocars, also commonly referred to as tunnelers, or introducers, having a cannula, stylet, and a guidewire stylet, inside a patient during a surgical procedure, such as a ventriculoperitoneal hydrocephalus shunt implantation, from a proximal entry point to a distal end point, in order to subcutaneously route and implant a medical device, such as shunt tubing, in a patient.. .
Chondroitin for use in medicine
Chondroitin, a metabolic intermediate of chondroitin sulphate biosynthesis in mammals and other living organisms, possesses biological properties different from those of chondroitin sulphate, and can be advantageously used for applications in the pharmaceutical, nutraceutical, cosmeceutical and medical device fields. Chondroitin has biostimulating, anti-inflammatory and anti-microbial activity and can be used in the treatment of osteoarthritis, eye disorders, interstitial cystitis, lung disorders, inflammatory disorders in general, oncological disorders, peritoneal dialysis, tissue biorevitalisation and wound repair, as a skin filler, and as bioresorbable scaffolds..
Reducing post-operative adhesion formation with intraperitoneal glutamine
Intraperitoneal administration of glutamine to reduce adhesions in the peritoneum of a patient.. .
Ade Therapeutics Inc.
Peritoneal dialysis fluid
The present invention is a sterile peritoneal dialysis fluid, including an acidic first liquid containing 60.0 to 94.0 g/l of icodextrin and 0 to 2.34 g/l of sodium chloride, and an alkaline second liquid containing an alkaline ph regulator, in which the first liquid after sterilization has a ph of 5.0 to 5.5, the second liquid after sterilization has a ph of 6.5 to 7.5, and a mixture of the first liquid and the second liquid after sterilization has a ph of 6.0 to 7.5. The present invention can provide a peritoneal dialysis fluid containing icodextrin, in which the stability of icodextrin during the heat sterilization and the subsequent storage can be improved to the maximum, and the ph of the peritoneal dialysis fluid is close to the physiological range..
Terumo Kabushiki Kaisha
Partially absorbable fiber-reinforced composites for controlled drug delivery
This invention describes a partially absorbable, fiber-reinforced composite in the form of a ring, or a suture-like thread, with modified terminals for use as a controlled delivery system of at least one bioactive agent, wherein said composite comprising an absorbable fiber construct capable of providing time-dependent mechanical properties of a biostable elastomeric matrix containing an absorbable microparticulate ion-exchanger to modulate the release of the bioactive agent(s) for a desired period(s) of time at a specific biological site; this can be a vaginal canal, peritoneal cavity, scrotum, prostate gland, an ear loop or subcutaneous tissue. Such drug delivery systems can be used for the local administration of at least one bioactive agent, including those used as contraceptive, antimicrobial, anti-inflammatory and/or antiviral agents as well as for cancer treatment..
Peritoneal dialysis fluid
The present invention is a sterile peritoneal dialysis fluid, including an acidic first liquid containing only icodextrin and 0 to 2.34 g/l of sodium chloride, and an alkaline second liquid containing an alkaline ph regulator, in which the first liquid after sterilization has a ph of 5.0 to 5.5, the second liquid after sterilization has a ph of 6.5 to 7.5, and a mixture of the first liquid and the second liquid after sterilization has a ph of 6.0 to 7.5. The present invention can provide a peritoneal dialysis fluid containing icodextrin, in which the stability of icodextrin during the heat sterilization and the subsequent storage can be improved to the maximum, and the ph of the peritoneal dialysis fluid is close to the physiological range..
Terumo Kabushiki Kaisha
Fluid line autoconnect medical treatment system
A medical infusion fluid handling system, such as an automated peritoneal dialysis system, may be arranged to de-cap and connect one or more lines (such as solution lines) with one or more spikes or other connection ports on a fluid handling cassette. This feature may reduce a likelihood of contamination since no human interaction is required to de-cap and connect the one or more lines and the one or more spikes.
Deka Products Limited Partnership
Optimizing peritoneal dialysis using a patient hand-held scanning device
A handheld personal communication apparatus for dialysis includes: a reader to (i) read a marking displayed on a dialysis fluid container to acquire data concerning at least one of a dialysis fluid type or a dialysis fluid volume from the marking, and/or (ii) receive a patient weight signal from a weight scale; a processor using at least one of the dialysis fluid type, dialysis fluid volume, or patient weight to determine a dialysis dwell time for at least one cycle of a dialysis therapy, the dialysis dwell time being a time to achieve, over the at least one cycle, at least one of (a) a specified ultrafiltrate level, (b) a urea removal level, or (c) a creatinine removal level; and an output interface providing an indication to the patient of a completion of the dialysis dwell time.. .
Baxter Healthcare S.a.
Portal and management of dialysis therapy
System and method for point-of-care monitoring of neutrophils in a peritoneal dialysis sample with the use of a microfluidic system. The immunoassay based chip is configured to bound neutrophils to a microfluidic channel surface while leaving auxiliary cells and particles unattached and suspended in the sample and flushable with a wash buffer.
Therapy with clostridium perfringens enterotoxin to treat ovarian and uterine cancer
The invention discloses high levels of receptors for clostridium perfringens enterotoxin (cpe) have been found in ovarian cancer and uterine cancer tissue samples. In addition, successful in vivo treatment of a mouse model of ovarian cancer with intraperitoneal injection of cpe is disclosed.
Viral fusion protein treatment for ccr8 mediated diseases
Compositions, methods, and kits are provided for treating ccr8 mediated diseases with applicability to atopic dermatitis and potential applicability to asthma, prurigo nodularis, nummular dermatitis, neurodeimatitis, and lichen simplex chronicus and some lymphomas, multiple sclerosis, acquired immunodeficiency disease, peritoneal adhesions, kaposi's sarcoma and atherogenesis—the expression of all of which, at least in part, is mediated by cells expressing the chemokine receptor ccr8. The compositions include proteins and fusion proteins from molluscum contagiosum virus (mcv) or variants, analogs and derivatives thereof which exhibit inhibitory activity.
Liposome composition for use in peritoneal dialysis
The present invention is directed to a liposome composition for use in the peritoneal dialysis of patients suffering from endogenous or exogenous toxicopathies, wherein the ph within the liposomes differs from the ph in the intraperitoneal cavity and wherein the ph within the liposome results in a liposome-encapsulated charged toxin. The invention also relates to a pharmaceutical composition comprising said liposomes.
Hemodialysis and peritoneal dialysis systems having electrodialysis and electrodeionization capabilities
Systems and methods for hemodialysis or peritoneal dialysis having integrated electrodialysis and electrodeionization capabilities are provided. In an embodiment, the dialysis system includes a carbon source, a urease source, an ed/edi unit.
Baxter Healthcare S.a.
Systems and methods for performing peritoneal dialysis
Systems and methods for providing multiple pass continuous flow dialysis are provided. In an embodiment, a system for providing peritoneal dialysis includes a catheter in communication with a peritoneal cavity, a fluid loop in fluid communication with the catheter and capable of circulating a therapy fluid into, through and out of the patient's peritoneal cavity, a multi-line fluid circuit, the multi-line fluid circuit in fluid communication with the fluid loop and including a bypass line coupled to a discharge fluid line, and a cycler including a plurality of valves, the cycler programmed to operate the plurality of valves to selectively (i) discharge therapy fluid from the multi-line fluid circuit via the discharge fluid line or (ii) bypass the discharge fluid line via the bypass line and circulate the therapy fluid a plurality of times through the fluid loop prior to exiting the multi-line fluid circuit via the discharge fluid line..
Baxter Healthcare S.a.
Composite absorbable/biodegradable rings for controlled drug delivery
A fiber-reinforced composite ring for the controlled release of at least one bioactive agent includes a biocompatible matrix reinforced with absorbable/biodegradable fibers capable of providing the mechanical properties needed for inserting and maintaining the ring in a body cavity for a desired period of time. Such ring system as can be used for the intravaginal, intraperitoneal, and subcutaneous delivery of at least one bioactive agent, including those used as contraceptives, antimicrobial agents, and/or antiviral agents, as well as those for the treatment of cancer..
Method of inexpensive transepithelial dialysis with hot water bath and sorbents
Current technologies to treat end stage renal disease (esrd) include peritoneal dialysis, hemodialysis and transplantation all of which are expensive. This invention is an inexpensive method to decrease body toxins that requires immersion of a body in a hot water bath with sorbents.
Method of mending a groin defect
A method of mending a groin defect such as an indirect inguinal hernia, a direct inguinal hernia, and/or a femoral hernia. A space between the external oblique aponeurosis and the internal oblique aponeurosis is dissected superiorly and laterally to create a site for receiving a lateral portion of a prosthetic repair patch.
Bard Shannon Limited
Peritoneal topics: Peritoneal, Peritoneal Dialysis, Peritoneal Cavity, Dialysis System, Intraperitoneal, Abdominal Cavity, Hemodialysis, Anastomosis, Wireless Communication Device, Colorectal, Hydrogen Sulfide, Sulfonamide, Ultraviolet, Ultraviolet Light, Subcutaneous
Follow us on Twitter
This listing is a sample listing of patent applications related to Peritoneal for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Peritoneal with additional patents listed. Browse our RSS directory or Search for other possible listings.